Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Sep;82(3):583-623.
doi: 10.1111/bcp.12975. Epub 2016 Jun 13.

The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis

Amy T Page  1 , Rhonda M Clifford  1 , Kathleen Potter  1 , Darren Schwartz  1   2 , Christopher D Etherton-Beer  1   3
Affiliations
Meta-Analysis

The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis

Amy T Page et al. Br J Clin Pharmacol. 2016 Sep.

Abstract

Aims: Deprescribing is a suggested intervention to reverse the potential iatrogenic harms of inappropriate polypharmacy. The review aimed to determine whether or not deprescribing is a safe, effective and feasible intervention to modify mortality and health outcomes in older adults.

Methods: Specified databases were searched from inception to February 2015. Two researchers independently screened all retrieved articles for inclusion, assessed study quality and extracted data. Data were pooled using RevMan v5.3. Eligible studies included those where older adults had at least one medication deprescribed. The primary outcome was mortality. Secondary outcomes were adverse drug withdrawal events, psychological and physical health outcomes, quality of life, and medication usage (e.g. successful deprescribing, number of medications prescribed, potentially inappropriate medication use).

Results: A total of 132 papers met the inclusion criteria, which included 34 143 participants aged 73.8 ± 5.4 years. In nonrandomized studies, deprescribing polypharmacy was shown to significantly decrease mortality (OR 0.32, 95% CI: 0.17-0.60). However, this was not statistically significant in the randomized studies (OR 0.82, 95% CI 0.61-1.11). Subgroup analysis revealed patient-specific interventions to deprescribe demonstrated a significant reduction in mortality (OR 0.62, 95% CI 0.43-0.88). However, generalized educational programmes did not change mortality (OR 1.21, 95% CI 0.86-1.69).

Conclusions: Although nonrandomized data suggested that deprescribing reduces mortality, deprescribing was not shown to alter mortality in randomized studies. Mortality was significantly reduced when applying patient-specific interventions to deprescribe in randomized studies.

Keywords: deprescribing; medication discontinuation; meta-analysis; older adults; polypharmacy; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection process for included papers
Figure 2
Figure 2
Risk of bias graph for all included randomized studies. formula image Low risk of bias, formula image unclear risk of bias, formula image high risk of bias
Figure 3
Figure 3
Mortality associated with deprescribing interventions to reduce polypharmacy (randomized studies)
Figure 4
Figure 4
Mortality associated with deprescribing interventions to reduce polypharmacy for subgroup analysis based on intervention technique (randomized studies)
Figure 5
Figure 5
Mortality associated with deprescribing interventions to reduce polypharmacy for subgroup analysis based on age (randomized studies)
Figure 6
Figure 6
Mortality associated with deprescribing interventions to reduce polypharmacy for subgroup analysis for participants living with dementia and cognitively intact participants (randomized studies)
See this image and copyright information in PMC

References

    1. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10: 430–9. - PubMed
    1. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta‐analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769–81. - PubMed
    1. Home PD, Pocock SJ, Beck‐Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet 2009; 373: 2125–35. - PubMed
    1. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta‐analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300. - PubMed
    1. Roehrborn CG, Siami P, Barkin J, Damião R, Major‐Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‐year results from the CombAT study. Eur Urol 2010; 57: 123–31. - PubMed